Order Article Reprints

Albiñana V, Gallardo-Vara E, de Rojas-P I, Recio-Poveda L, Aguado T, Canto-Cano A, Aguirre DT, Serra MM, González-Peramato P, Martínez-Piñeiro L, et al. Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel–Lindau Disease. Journal of Clinical Medicine. 2020; 9(9):2740. https://doi.org/10.3390/jcm9092740

Albiñana, Virginia, Eunate Gallardo-Vara, Isabel de Rojas-P, Lucia Recio-Poveda, Tania Aguado, Ana Canto-Cano, Daniel T. Aguirre, Marcelo M. Serra, Pilar González-Peramato, Luis Martínez-Piñeiro, and et al. 2020. "Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel–Lindau Disease" Journal of Clinical Medicine 9, no. 9: 2740. https://doi.org/10.3390/jcm9092740

Albiñana, V., Gallardo-Vara, E., de Rojas-P, I., Recio-Poveda, L., Aguado, T., Canto-Cano, A., Aguirre, D. T., Serra, M. M., González-Peramato, P., Martínez-Piñeiro, L., Cuesta, A. M., & Botella, L. M. (2020). Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel–Lindau Disease. Journal of Clinical Medicine, 9(9), 2740. https://doi.org/10.3390/jcm9092740